Explore our corporate updates and press releases below. For the latest news, follow us on LinkedIn.
To learn more about our company, visit our Corporate Overview page. To see our progress toward new answers and disease-centric therapies, visit our Pipeline page or review recent articles and studies on our Publications page.
|08/12/2021||August 2021 Update||Corporate Update|
|08/06/2021||Ichnos Sciences Nominates Innate Modulator ISB 1442 as Next Clinical Candidate for Treatment of Relapsed/Refractory Multiple Myeloma||Press Release|
|06/04/2021||Ichnos Sciences Presents Preclinical Data Confirming Potential for ISB 1342 in Relapsed/Refractory Multiple Myeloma at 2021 ASCO Annual Meeting||Press Release|
|05/27/2021||May 2021 Update||Corporate Update|
|05/21/2021||Chief Executive Officer Alessandro Riva, M.D., to Leave Ichnos Sciences||Updates|
|05/03/2021||Ichnos Sciences Presents Positive Data from Ongoing Phase 2b Study of Telazorlimab in Atopic Dermatitis at the 2021 SID Virtual Meeting||Press Release|
|04/05/2021||Ichnos Sciences Appoints Cyril Konto, M.D., Chief Medical Officer||Press Release|
|03/19/2021||Alessandro Riva Interview Featured in Pharma Boardroom||Updates|
|03/02/2021||Ichnos Sciences Appoints Michael D. Price as CFO||Press Release|
|02/11/2021||February 2021 Update||Corporate Update|
The links above are provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.